Forum of Clinical Oncology最新文献_第4页

Cryptosporidium and colorectal cancer: a review of epidemiology and possible association 隐孢子虫与癌症的流行病学及可能的关联

Forum of Clinical Oncology Pub Date : 2021-12-01 DOI: 10.2478/fco-2021-0009

Oyetunde T. Oyeyemi, I. Oyeyemi, N. Alamukii, Jennifer K. Kone, Olawunmi R. Oyerinde, I. A. Anuoluwa, O. Ovuakporie-Uvo, I. Adesina, Yinka D. Oluwafemi, S. Ogoanah, A. Tiamiyu

引用次数: 0

Clinicopathological characteristics in women with breast cancer in extreme ages in Greece: A single centre experience 希腊极端年龄妇女乳腺癌的临床病理特征:单一中心经验

Forum of Clinical Oncology Pub Date : 2021-12-01 DOI: 10.2478/fco-2021-0007

C. Karachalios, E. Karamitrousis, Panagiotis Daskalakis

{"title":"Clinicopathological characteristics in women with breast cancer in extreme ages in Greece: A single centre experience","authors":"C. Karachalios, E. Karamitrousis, Panagiotis Daskalakis","doi":"10.2478/fco-2021-0007","DOIUrl":"https://doi.org/10.2478/fco-2021-0007","url":null,"abstract":"Abstract Introduction Breast cancer is the most common malignancy in Greek women. The highest incidence occurs in patients aged 40–70 years. However, the emergence of the disease in women under 40 and over 80 years old is a significant problem in everyday practice, because of the diagnostic and therapeutic challenges for these age groups. The objective of this study is to investigate clinicopathological characteristics of Greek women under 40 and over 80 diagnosed with breast cancer during 2019–2020 in a specialized Breast Cancer Surgical Centre, as well as the pathological characteristics of their disease and the therapeutic measures applied to these women. Aim of the study The aim of this study is to compare clinical and pathological characteristics of breast cancer in a group of Greek premenopausal women younger than 40 years of age with a group of elderly women older than 80 years old, who were treated in a surgical breast centre in Greece during the last two years. Patients and Methods During the last 2 years, 21 women under 40 and 22 women older than 80 were diagnosed with breast cancer in our Centre. Results Invasive ductal adenocarcinoma was the most frequent histological type for both Groups: Most younger women underwent surgery followed by chemotherapy, while the majority of older patients received hormonal therapy after surgery. Conclusions There were no statistically significant differences between women under 40 and women over 80 in the study sample regarding their clinicopathological characteristics. However, younger women underwent more therapeutic modalities (i.e.adjuvant treatments in addition to surgery) than older ones.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"49 - 55"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42845691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sialic acids: An Avenue to Target Cancer Progression, Metastasis, and Resistance to Therapy 唾液酸：靶向癌症进展、转移和耐药性的途径

Forum of Clinical Oncology Pub Date : 2021-12-01 DOI: 10.2478/fco-2021-0006

M. Goni, P. K. Javaregowda, V. Chachadi, D. Virupakshaiah

{"title":"Sialic acids: An Avenue to Target Cancer Progression, Metastasis, and Resistance to Therapy","authors":"M. Goni, P. K. Javaregowda, V. Chachadi, D. Virupakshaiah","doi":"10.2478/fco-2021-0006","DOIUrl":"https://doi.org/10.2478/fco-2021-0006","url":null,"abstract":"Abstract Background Sialic acids are alpha-keto acids with nine carbons that are commonly present in the terminal sugars of glycans on glycoproteins and glycolipids on the cell surface. Sialic acids have a role in a variety of physiological and pathological processes by interacting with carbohydrates and proteins, communicating between cells, and acting as cell surface receptors for viruses and bacteria. Several studies have shown the aberrant pattern of sialic acids on cancer cells due to change in their glycosylation status. This pattern may be attributed to various physiological and pathological changes occurring in tumour cells. Hypersialylation in tumours, its involvement in tumour growth, immune evasion and escape from the apoptotic pathway, metastasis formation, and therapeutic resistance have all been fairly well investigated. Methods A PubMed search was conducted and published articles in different studies from 2000 to 2020 were included and reviewed. Here, we discuss current outcomes that emphasize the unfavourable effects of hypersialylation on multiple aspects of tumour genesis, immune evasion, metastasis and resistance to therapy. Conclusion These recent investigations have found that aberrant sialylation is an essential process for tumour cells to evade immune surveillance and maintain their malignancy. Together, these noteworthy views provide a solid platform for designing and developing therapeutic approaches that target hypersialylation of cancer cells.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"40 - 48"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44124408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Outcomes of Port A Catheter Implantations in Cancer Patients: Experience in 102 Cases 102例肿瘤患者A口置管效果分析

Forum of Clinical Oncology Pub Date : 2021-12-01 DOI: 10.2478/fco-2021-0008

E. Ilkeli

{"title":"Outcomes of Port A Catheter Implantations in Cancer Patients: Experience in 102 Cases","authors":"E. Ilkeli","doi":"10.2478/fco-2021-0008","DOIUrl":"https://doi.org/10.2478/fco-2021-0008","url":null,"abstract":"Abstract Aim This study evaluates cancer patients undergoing port catheter implantation. Patients and methods The study was conducted among patients admitted to the cardiovascular department of Düzce State Hospital from June 2018 to July 2020. The inclusion criterion was the implantation of a vascular port for at during 2 years. One hundred and two patients were enrolled in the study. The most common acute outcomes such as pneumothorax, haemothorax, thoracic duct damage and cardiac tamponade and the demographic characteristics of all patients were recorded. Patients were evaluated for the late complications of port catheter, such as thrombosis, infection and kinking, catheter fracture and occlusion. Results Complications of port catheter occurred early (≤30 days) and delayed (>30 days) at rates of up to 8% and 15%, respectively. The most common early and late complications were pneumothorax and non-functional port (occlusion, thrombosis, kinking), respectively. Conclusions Thrombosis is the most common cause of dysfunction in central port catheters used in the treatment of cancer patients. Routine radiological imaging can help in early detection of catheter-related complications.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"56 - 60"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45015027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival Study in Pediatric Patients with Medulloblastoma in a General Hospital in Tehran, Iran 伊朗德黑兰一家综合医院小儿髓母细胞瘤患者的生存研究

Forum of Clinical Oncology Pub Date : 2021-12-01 DOI: 10.2478/fco-2021-0004

S. Tahbaz, H. Yahyazadeh, M. Beheshti

{"title":"Survival Study in Pediatric Patients with Medulloblastoma in a General Hospital in Tehran, Iran","authors":"S. Tahbaz, H. Yahyazadeh, M. Beheshti","doi":"10.2478/fco-2021-0004","DOIUrl":"https://doi.org/10.2478/fco-2021-0004","url":null,"abstract":"Abstract Brain tumours are the most common solid tumours that afflict the pediatric population. Me-dulloblastoma (MB) is the most common malignant brain tumour in children, constituting nearly 20% of all pediatric brain tumours. This study is an evaluation of overall survival rate of pediatric MB tumour patients after one year, three years, five years, and ten years according to case studies. From 22 June 2009 to 19 December 2019, a total of 22 patients ranging in age from 1 to 14 years old underwent tumour removal. These patients were followed to determine survival rate. Tumours were classified into three pathological subtypes: The first was classic MB, the second was desmoplastic nodular MB and MB with extensive nodularity, and the third was large cell and anaplastic MB. Patients who were 3 years old or older had a better survival rate than younger patients (log-rank test; p = 0.01). The survival probability in the older children group (55%) was significant compared to the group of younger children (29%). The Kaplan–Meier survival curves of the patients were significantly different. The ten-year survival rates in the average- and high-risk groups were 64.4% and 86.0%, respectively. After a follow-up of 120 months (median range = 60 months), recurrence or progression was observed in 22 patients and 15 patients were still alive. The estimated 10-year overall survival rates for all patients were 49.36 ± 38.33. MB patients’ survival rate was quite good in our hospital. More than half of the patients, most of whom had large cell anaplastic and classic type MB, survived the 10-year follow-up period without any problems.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"34 - 39"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48593377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of bioflavonoid containing chemotherapeutic delivery systems for UV-damaged skin and kangri cancer 含生物类黄酮的紫外线损伤皮肤和癌症化学治疗系统的研制

Forum of Clinical Oncology Pub Date : 2021-12-01 DOI: 10.2478/fco-2021-0012

Harish Sharma, G. Sahu, C. Kaur

{"title":"Development of bioflavonoid containing chemotherapeutic delivery systems for UV-damaged skin and kangri cancer","authors":"Harish Sharma, G. Sahu, C. Kaur","doi":"10.2478/fco-2021-0012","DOIUrl":"https://doi.org/10.2478/fco-2021-0012","url":null,"abstract":"Abstract Background The lower abdomen and inner thighs are most likely to become affected by kangri cancer because those areas are exposed to continuous exposure to kangri. Objective In this article, formulation and characterization of a water-in-oil microemulsion of 5-fluorouracil with rutin (R-5FU) for better skin penetration and inhibition of kangri cancer (skin cancer surfactant) is discussed. Method To produce R-5-FU microemulsions, surfactant-cosurfactant was mixed with oil. Distilled water was added dropwise with the help of a burette by gentle stirring at a constant temperature. The surfactant and co-surfactant were mixed into three particular ratios 1:1, 2:1, and 3:1. Further characterizations were performed, such as visual inspection and thermodynamic stability including a stress test and centrifugation. In visual inspection included assessment of the colour, homogeneity, and odour of the formulation of FU microemulsion. Result All three microemulsions, labeled RME1, RME2, and RME3, are highly stable. An oval shape of surface morphology of 5-FU was noticed by using a TEM image. The viscosity of RME3 was found to be 17.25±0.22 pa-s. The average globule size was 100–300 nm for all three RME. The results of human cadaver skin permeability are almost of the same pattern, butRME3 indicates the best skin permeability with negligible side effects on the skin. Conclusion The quantity of 5-FU released from all formulations at 3-hr ranged from 95.57% to 83.67%. None of the three formulations resulted in skin irritation, with irritancy score of zero (IS=0). Observation revealed no lysis, hemorrhage, or coagulation after application.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"86 - 98"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46156869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Oncological outcomes of testicular cancer patients: 10 years of experiences resulting from a single university-based hospital 睾丸癌患者的肿瘤预后:一家大学附属医院的10年经验

Forum of Clinical Oncology Pub Date : 2021-07-31 DOI: 10.2139/ssrn.3897013

Tanan Bejrananda, Komsan Leetanaporn, N. Pruphetkaew, M. Tanthanuch

{"title":"Oncological outcomes of testicular cancer patients: 10 years of experiences resulting from a single university-based hospital","authors":"Tanan Bejrananda, Komsan Leetanaporn, N. Pruphetkaew, M. Tanthanuch","doi":"10.2139/ssrn.3897013","DOIUrl":"https://doi.org/10.2139/ssrn.3897013","url":null,"abstract":"Abstract Purpose To explore clinical and pathological characteristics of testicular cancer and also identify factors associated with its oncological outcomes. Testicular cancer has a very good prognosis. Actually, we aim to report on 10 years of experience in the real-world practice of treating testicular cancer in a university-based hospital. Methods This is a retrospective cohort study of testicular cancer patients in Songklanagarind hospital; from January 2007 and December 2016, all eligible testicular cancer patients were included. Clinical characteristics (age, physical examination findings, tumour markers, histopathology, clinical stage, and initial treatment) and clinical outcomes were collected. These patients were divided into two groups: seminoma patients (seminomas) and non-seminoma patients (non-seminomas). Clinical characteristics and outcomes of treatment were analysed, and factors associated with oncological outcomes were identified. Results In 45 patients, median age 33 years, with diagnosis of testicular cancer, seminomas and non-seminomas were responsible for 23 (52.8%) and 22 (49%) of the cases, respectively. The median time of follow-up was 80.6 months (range: 1.8 to 120 months). The five-year OS was 94.7% and 57.1% in the seminoma and non-seminoma groups, respectively. For non-seminomas, five-year OS were 71.4%, 50%, and 42.9% in stage Ib–IIIa, IIIb, and IIIc, respectively, and for seminoma they were 92.3% and 100% in stage Ib–IIIa and IIIb, respectively. Multivariable analysis showed that non-seminoma, higher staging, and higher IGCCC risk were associated with poorer survival, significantly (p < 0.05). Conclusions Seminoma has a good prognosis and survival at all stages, whereas, in the non-seminoma group, higher staging and IGCCC risk were independent factors associated with a poorer prognosis.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"77 - 85"},"PeriodicalIF":0.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47288986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of vitamin D serum levels on clinicopathological features and outcome in advanced pancreatic carcinoma 血清维生素D水平对晚期胰腺癌临床病理特征和预后的影响

Forum of Clinical Oncology Pub Date : 2021-05-01 DOI: 10.2478/fco-2021-0015

Amrallah A. Mohammed, R. Salem

{"title":"Impact of vitamin D serum levels on clinicopathological features and outcome in advanced pancreatic carcinoma","authors":"Amrallah A. Mohammed, R. Salem","doi":"10.2478/fco-2021-0015","DOIUrl":"https://doi.org/10.2478/fco-2021-0015","url":null,"abstract":"Abstract Background Growing evidence encourages the preventive role of vitamin D in pancreatic carcinoma (PC). Meanwhile, the prognostic or predictive role needs more investigations. This study aimed to evaluate the correlation between serum vitamin D levels and the clinicopathological features with the outcome in advanced pancreatic carcinoma (APC). Materials and methods The current prospective study included 176 patients with APC. Assessing 25-hydroxy vitamin D is the most accurate method to measure the serum vitamin D levels. Serum vitamin D levels <20 ng/ml are defined as vitamin D deficiency, while levels ranging from 20 to 29 ng/ml are defined as vitamin D insufficiency. Before any treatment modalities were administered, the serum vitamin D levels were measured by enzyme-linked immunosorbent assay (ELISA). Results Serum vitamin D insufficiency and deficiency were detected in 28.4% and 31.8%, respectively. A large tumor size, higher grade, liver metastasis, higher serum level of CA 19-9, poor ECOG PS, and low overall response rate (ORR) were associated with lower serum vitamin D levels (p = 0.000). The median follow-up period was 7.6 months (range 0.6–18.6). The ORR was 23.2%, 54%, and 82.9% of vitamin D deficiency, insufficiency, and normal levels of vitamin D, respectively. The median OS was 11.4 months for patients with normal serum vitamin D levels, compared with 2.7 and 7.03 months for serum vitamin D deficiency and insufficiency, respectively. Conclusions Among patients with APC, serum vitamin D levels are considered a promising prognostic factor. It is associated with various poor prognostic features and worse survival outcome.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"22 - 30"},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42424717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Oral Complications of Head and Neck Cancer Therapy 头颈部肿瘤治疗的口腔并发症

Forum of Clinical Oncology Pub Date : 2021-05-01 DOI: 10.2478/fco-2019-0016

M. Kouri, A. Vadalouca, V. Kouloulias, Erofili Papadopoulou, E. Vardas, Euthimios Kyrodimos, M. Trichas, Evangelos Galitis, A. Zygogianni, Z. Liakouli, O. Nicolatou‐Galitis, A. Psyrri

引用次数: 2

Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety 低剂量卡培他滨与标准剂量卡培他滨治疗转移性乳腺癌的疗效和安全性比较研究

Forum of Clinical Oncology Pub Date : 2021-05-01 DOI: 10.2478/fco-2019-0015

E. Aboelnaga, W. El-beshbishi

{"title":"Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety","authors":"E. Aboelnaga, W. El-beshbishi","doi":"10.2478/fco-2019-0015","DOIUrl":"https://doi.org/10.2478/fco-2019-0015","url":null,"abstract":"Abstract Background A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose. Patients and methods Patients were enrolled in two groups. Group 1 included 21 patients who received the standard dose of capecitabine (1250 mg/m2 twice daily [BID] for 14 days), while the patients in group 2 (19 patients) received lower dose of capecitabine (850 mg/m2 BID for 14 days) every 3 weeks. Results In group 1, dose reduction was reported in 12 (57.1%) patients versus 1 patient in group 2 (5.3%; P = 0.0005). Patients in group 1 reported higher toxicity rates without any significant difference between the groups. The median duration of response was 17 weeks in group 1, while it was 19 weeks in group 2. Disease progression was recorded in 10 (47.6%) patients in group 1 versus 8 (42.1%) patients in group 2 (P = 0.81). The mean time to progression was 8.16 ± 0.63 months and the median was 10.1 months in group 1, while the mean was 8.98 ± 0.75 months and the median was 10 months in group 2 (P = 0.66). The overall survival had a mean of 11.94 ± 0.754 and 11.24 ± 0.665 months, while the median was 13.1 and 13 months in groups 1 and 2, respectively (P = 0.9). Conclusions A lower dose of capecitabine provides MBC patients with an active therapy that can be continued for prolonged periods to achieve long-term disease control without compromising its antitumor activity.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"12 - 21"},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46365992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0